VBI VACCINES INC (VBIV)
CA91822J2020 - Common Stock
Taking everything into account, VBIV scores 3 out of 10 in our fundamental rating. VBIV was compared to 588 industry peers in the Biotechnology industry. VBIV may be in some trouble as it scores bad on both profitability and health. VBIV is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
VBIV had negative earnings in the past year.
VBIV had a negative operating cash flow in the past year.
In the past 5 years VBIV always reported negative net income.
In the past 5 years VBIV always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -107.93%, VBIV is doing worse than 79.79% of the companies in the same industry.
The Return On Equity of VBIV (-1246.79%) is worse than 83.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -107.93% | ||
| ROE | -1246.79% | ||
| ROIC | N/A |
ROA(3y)-71.38%
ROA(5y)-56.21%
ROE(3y)-490.56%
ROE(5y)-312.13%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for VBIV so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VBIV does not have a ROIC to compare to the WACC, probably because it is not profitable.
VBIV has more shares outstanding than it did 1 year ago.
The number of shares outstanding for VBIV has been increased compared to 5 years ago.
VBIV has a worse debt/assets ratio than last year.
2.2 Solvency
VBIV has an Altman-Z score of -11.80. This is a bad value and indicates that VBIV is not financially healthy and even has some risk of bankruptcy.
VBIV's Altman-Z score of -11.80 is on the low side compared to the rest of the industry. VBIV is outperformed by 78.77% of its industry peers.
VBIV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.8 |
ROIC/WACCN/A
WACC9.6%
2.3 Liquidity
VBIV has a Current Ratio of 0.48. This is a bad value and indicates that VBIV is not financially healthy enough and could expect problems in meeting its short term obligations.
VBIV has a Current ratio of 0.48. This is amonst the worse of the industry: VBIV underperforms 95.38% of its industry peers.
A Quick Ratio of 0.37 indicates that VBIV may have some problems paying its short term obligations.
VBIV has a worse Quick ratio (0.37) than 96.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.48 | ||
| Quick Ratio | 0.37 |
3. Growth
3.1 Past
VBIV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -2060.47%.
Looking at the last year, VBIV shows a very strong growth in Revenue. The Revenue has grown by 696.61%.
The Revenue has been growing by 20.91% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-2060.47%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q87.5%
Revenue 1Y (TTM)696.61%
Revenue growth 3Y101.58%
Revenue growth 5Y20.91%
Revenue growth Q2Q194.14%
3.2 Future
Based on estimates for the next years, VBIV will show a very strong growth in Earnings Per Share. The EPS will grow by 31.86% on average per year.
The Revenue is expected to grow by 54.28% on average over the next years. This is a very strong growth
EPS Next Y91%
EPS Next 2Y31.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year50.43%
Revenue Next 2Y54.28%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VBIV. In the last year negative earnings were reported.
Also next year VBIV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VBIV's earnings are expected to grow with 31.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.86%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for VBIV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VBI VACCINES INC
NASDAQ:VBIV (4/24/2024, 7:00:01 PM)
0.59
-0.02 (-3.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap16.70M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -107.93% | ||
| ROE | -1246.79% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.48 | ||
| Quick Ratio | 0.37 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-2060.47%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y91%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)696.61%
Revenue growth 3Y101.58%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y